10-Q: OmniAb Q3 2025: Revenue Declines Amid R&D Investment

OmniAb reported a significant decline in Q3 2025 revenue and an increased net loss, despite a recent $30 million private placement.

Summary

• Net loss for the three months ended September 30, 2025, was $16.525 million, compared to $16.373 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $50.600 million, compared to $48.965 million for the same period in 2024.
• Total revenue for Q3 2025 decreased by 46% to $2.239 million from $4.172 million in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by 34% to $10.290 million from $15.587 million in the same period of 2024.
• Research and development expenses decreased by 22% in Q3 2025 to $10.379 million and by 19% for the nine months to $33.845 million, primarily due to lower personnel and external expenses.
• General and administrative expenses decreased by 4% in Q3 2025 to $6.777 million and by 4% for the nine months to $22.376 million, mainly due to lower legal fees and share-based compensation.
• Cash, cash equivalents, and short-term investments totaled $59.5 million as of September 30, 2025.
• A private placement (August 2025 PIPE) was completed on August 26, 2025, raising approximately $30.0 million in gross proceeds.
• As of September 30, 2025, OmniAb had 104 active partners with 399 active programs, including 28 OmniAb-derived antibodies in clinical development and three approved products.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and reduced operating cash burn, the significant decline in revenue across multiple categories and the increased net loss indicate ongoing financial challenges. The reliance on future partner success and out-of-the-money warrants also adds uncertainty.

Positives

• Successfully completed a private placement (August 2025 PIPE) raising approximately $30.0 million in gross proceeds.
• Cash, cash equivalents, and short-term investments of $59.5 million are believed to be sufficient to support operations for at least the next 12 months.
• Realized a gain of $3.0 million from the sale of a small molecule Kv7.2 program to Angelini Pharma S.p.A. in May 2025.
• Increased active partners to 104 (from 91 at December 31, 2024) and active programs to 399 (from 363 at December 31, 2024).
• 28 OmniAb-derived antibodies are in clinical development by partners, with one under regulatory review and three approved products.
• Net cash used in operating activities decreased to $30.781 million for the nine months ended September 30, 2025, from $35.792 million in the prior year.

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by 46% to $2.239 million from $4.172 million in the prior year.
• Total revenue for the nine months ended September 30, 2025, decreased by 34% to $10.290 million from $15.587 million in the prior year.
• Net loss increased to $16.525 million for Q3 2025 from $16.373 million in Q3 2024.
• Net loss increased to $50.600 million for the nine months ended September 30, 2025, from $48.965 million in the prior year.
• License and milestone revenue declined by 55% in Q3 2025 and 26% for the nine months, primarily due to a decrease in milestone revenue.
• Service revenue declined by 52% in Q3 2025 and 47% for the nine months, mainly due to the completion or discontinuation of certain small molecule ion channel programs.
• Royalty revenue declined by 31% for the nine months ended September 30, 2025, due to lower net sales from partners' product sales in China.
• Warrants are currently 'out of the money' (exercise price $11.50 per share), meaning cash proceeds from their exercise are not expected.

Risks

• Dependence on partners for the successful development and commercialization of therapies based on OmniAb's platform.
• Significant uncertainty in the timing and likelihood of reaching marketing authorization in drug discovery and development, impacting future royalty payments.
• Inability to control the progression, clinical development, regulatory strategy, or eventual commercialization of programs discovered using the platform.
• Reliance on partners to provide timely and accurate information for key business metrics, which may impact the accuracy of business evaluations.
• Recent government healthcare reform and other legislative measures, such as the One Big Beautiful Bill Act and drug pricing policies, could adversely affect partners' ability to sell products profitably, thereby impacting OmniAb's business and results of operations.
• Potential need to raise additional capital if anticipated cash flows are insufficient, with no assurance that such financing will be available on acceptable terms or at all.
• Expectation to continue incurring losses as investments are made in R&D, marketing, and operational infrastructure.

Future Outlook

OmniAb expects to continue incurring losses as it invests in research and development, marketing, and operational infrastructure. Existing cash, cash equivalents, and short-term investments are projected to support operations for at least the next 12 months. Future capital requirements are dependent on revenue growth, expansion costs, R&D activities, competitive developments, intellectual property costs, and potential acquisitions. The long-term value is anticipated to be driven by royalties from partner programs, while shorter-term revenue will be from milestones, though significant uncertainty exists regarding the timing and likelihood of marketing authorization for drug candidates.

Management Comments

• "Our ability to continue its operations is dependent upon its ability to generate cash flows from operations and potentially obtain additional capital in the future."
• "We believe its existing cash, cash equivalents and short-term investments are sufficient to support operations through at least the next 12 months from the date of issuance of these financial statements."
• "We believe the OmniAb animals comprise the most diverse host systems available in the industry."
• "We succeed when our partners are successful, and our agreements are structured to align economic and scientific interests."
• "We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments."
• "We believe our revenue will be materially driven by milestones in the shorter term, and by royalties in the longer term, from our partnered programs."
• "We do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform, and as a result, we are dependent on our partners efforts and decisions with respect to such programs."

Industry Context

OmniAb operates in the biotechnology sector, specializing in licensing discovery research technology for next-generation therapeutics, particularly focusing on antibody discovery. The company's platform leverages 'Biological Intelligence' and integrates in silico, artificial intelligence, and machine learning tools, positioning it within the innovative segment of drug discovery. The industry faces increasing pressure from government healthcare reforms and legislative measures aimed at reducing biopharmaceutical product prices, which could impact the profitability of OmniAb's partners and, consequently, its own revenue streams derived from milestones and royalties. The company's business model, relying on partner success for downstream payments, is common in the biotech licensing landscape, where platform technologies are licensed to larger pharmaceutical companies for development and commercialization.

Comparison to Industry Standards

• OmniAb states that its 'OmniAb animals comprise the most diverse host systems available in the industry,' positioning its core technology as a leader in repertoire generation.
• Typical royalty rates for antibody discovery contracts are currently in the lowto mid-single digits, which is a common range for early-stage platform technology licensing in the biopharmaceutical industry, though specific rates can vary based on deal structure and therapeutic area.

Legal Proceedings

• The company is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.
• Acknowledges that litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• The August 2025 PIPE included purchasers who were officers, directors, employees, or consultants of the company, who purchased shares at a price of $1.85 per share, compared to $1.40 per share for other purchasers.

Stakeholder Impact

• Shareholders: Experienced dilution from the August 2025 PIPE (21,254,106 shares issued) and face potential future dilution from the ATM facility and warrant exercises. Continued net losses may negatively impact shareholder value.
• Employees: Lower personnel expenses and headcount contributed to reduced R&D costs. Share-based compensation remains a significant component of employee incentives.
• Partners: The company's financial performance and future growth are heavily reliant on the success of its partners in developing and commercializing therapies using OmniAb's platform.
• Creditors: The company's liquidity position is supported by the recent capital raise, but ongoing losses could be a concern if not effectively managed.

Next Steps

• Continue investing in research and development activities to improve the technology platform.
• Market and sell technologies to existing and new partners.
• Add operational, financial, and management information systems and personnel.
• Potentially raise additional capital in the future to expand the business, pursue strategic investments or acquisitions, or for other reasons.
• Evaluate the impact of adopting ASU 2024-03 on consolidated financial statements and disclosures (effective for annual reporting periods beginning after December 15, 2026).

Key Dates

Recommendation

While OmniAb successfully raised capital and reduced its operating cash burn, the substantial decline in revenue across key segments and the increased net loss are concerning. The growth in active partners and programs indicates underlying platform utility, but the path to profitability remains uncertain and heavily dependent on partner success and future royalty streams, which are long-term and unpredictable. The current 'out of the money' status of warrants further limits immediate upside from financing. Investors should hold to monitor the impact of the recent capital raise and the progression of partnered programs, especially those in clinical development, before making further commitments.

Keywords

Biotechnology, Antibody discovery, Drug development, SEC filing, 10-Q, Financial results, Biopharmaceutical, Therapeutics, License revenue, Milestone payments, Royalty revenue, Research and development, Clinical development, Capital raise, Healthcare reform